RA patients will trade efficacy for less frequent, shorter treatment

RA patients will trade efficacy for less frequent, shorter treatment
Based on hypothetical scenarios, rheumatoid arthritis patients would accept treatments with lower efficacy and greater risk to achieve lower duration and frequency, according to research published in the July issue of Arthritis Care & Research.

(HealthDay)—Based on hypothetical scenarios, rheumatoid arthritis (RA) patients would accept treatments with lower efficacy and greater risk to achieve lower duration and frequency, according to research published in the July issue of Arthritis Care & Research.

Christine Poulos, Ph.D., from RTI Solutions in Research Triangle Park, N.C., and colleagues surveyed 901 patients with a self-reported physician diagnosis of moderate to severe RA regarding hypothetical treatment choices (396 in an online panel and 505 as part of the RA Information, Service, and Education group). Relative importances were estimated for six attributes included in all treatment choices: response rate, mode of administration, treatment duration, treatment frequency, and the risks of immediate mild and serious treatment reactions.

The researchers found that the marginal utility of changes in treatment features was largest for a one-hour change in treatment duration, while a one-unit change in the annual frequency of treatment was the second least important change. For annual treatment frequency, the marginal utility of changes depends on the treatment duration and vice versa.

"Respondents would accept treatments with lower efficacy and greater risk to achieve lower duration and frequency," the authors write. "Previous studies have linked patient preferences to treatment adherence, suggesting that reductions in duration or frequency could improve adherence and health outcomes."

One author is an employee of Genentech, which sponsored the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Higher disease activity scores in obese RA patients

Jun 11, 2014

A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that obese patients with rheumatoid arthritis (RA) have higher DAS (disease activity) scores than non-obese patients, ...

Biologic treatments for RA carry similar infection risk

Jul 28, 2014

(HealthDay)—The risk of hospitalized bacterial infections in older rheumatoid arthritis (RA) patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, ...

Data suggest smoking doesn't impact RA treatment response

Dec 21, 2012

(HealthDay)—For patients with early rheumatoid arthritis (RA), smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according ...

Recommended for you

Sickle cell trait tied to increased pulmonary embolism risk

3 hours ago

(HealthDay)—For African-Americans, sickle cell trait is associated with an increased risk of pulmonary embolism, but not deep vein thrombosis, according to a study published online Nov. 13 in the Journal of Thrombosis an ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.